Cargando…
Corrigendum to “A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells” [Neoplasia 18 (2016) 199-212]
Autores principales: | Chen, Chi-Wei, Wu, Ming-Hsi, Chen, Yi-Fan, Yen, Tsai-Yi, Lin, Yi-Wen, Chao, Shu-Hsin, Tala, Satishkumar, Tsai, Tung-Hu, Su, Tsann-Long, Lee, Te-Chang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156521/ https://www.ncbi.nlm.nih.gov/pubmed/27978996 http://dx.doi.org/10.1016/j.neo.2016.10.005 |
Ejemplares similares
-
A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells()()
por: Chen, Chi-Wei, et al.
Publicado: (2016) -
Corrigendum to “PI3K Inhibition Augments the Therapeutic Efficacy of a 3a–aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells [Translational Oncology 7 (2014) 256–266.e5]
por: Sanjiv, Kumar, et al.
Publicado: (2017) -
Corrigendum to “Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis” [Neoplasia 19.9 (2017) 716-733]
por: Tati, Swetha, et al.
Publicado: (2017) -
miR-199b-5p serves as a tumor suppressor in renal cell carcinoma
por: Lai, Yulin, et al.
Publicado: (2018) -
PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells()()
por: Sanjiv, Kumar, et al.
Publicado: (2014)